Impax Laboratories, Inc.
IPXL
IPXL was delisted on the 4th of May, 2018.
196 hedge funds and large institutions have $1.46B invested in Impax Laboratories, Inc. in 2016 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 92 increasing their positions, 56 reducing their positions, and 34 closing their positions.
64% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 56
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 34
1% less funds holding
Funds holding: 198 → 196 (-2)
23% less capital invested
Capital invested by funds: $1.9B → $1.46B (-$434M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $6.91M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$28.9M |
| 2 |
VOYA Investment Management
Atlanta,
Georgia
|
+$26M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$25.8M |
| 4 |
NIMC
NWQ Investment Management Company
Los Angeles,
California
|
+$23.7M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$17.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Aravt Global
New York
|
-$64.3M |
| 2 |
O
OrbiMed
New York
|
-$56.4M |
| 3 |
PCM
Pennant Capital Management
Summit,
New Jersey
|
-$56.2M |
| 4 |
GAM
Gotham Asset Management
New York
|
-$21.1M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$19.8M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
226
US Bancorp
Minneapolis,
Minnesota
| – | -$4K | -149 | Closed |
|
|
CCA
227
Checchi Capital Advisers
Beverly Hills,
California
| – | -$3K | -107 | Closed |
|
228
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$2K | -65 | Closed |
|
IPXL Hedge Fund Activity: Q3 2016 in Review
196 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Impax Laboratories, Inc. (IPXL) for Q3 2016, worth a combined $1.46B — down 23% from $1.9B a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of IPXL and 33 opened new positions — a net loss of 1 holder — while 56 trimmed existing stakes and 92 added.
The largest buyer was EverPoint Asset Management, opening a new position worth an estimated $28.9M. The largest seller was Aravt Global, exiting entirely with an estimated $64.3M sold.
- 196 institutional investors held Impax Laboratories, Inc. (IPXL) as of Q3 2016, down from 198 in Q2 2016.
- Funds reported $1.46B of Impax Laboratories, Inc. stock for Q3 2016, down 23% quarter-over-quarter.
- 33 funds opened new Impax Laboratories, Inc. positions in Q3 2016 and 34 closed out, a net change of -1 holder.
- The largest Impax Laboratories, Inc. buyer in Q3 2016 was EverPoint Asset Management, an estimated $28.9M added.
- The largest Impax Laboratories, Inc. seller in Q3 2016 was Aravt Global, an estimated $64.3M sold.
Based on aggregated 13F filings for Q3 2016.